FULL VET CRO

OCR, your partner for comparative medicine studies

OCR is specialized in the design of clinical studies of pets with naturally occurring pathologies
for efficacy assessment of drug candidates and medical devices for Human Health.

MEET WITH OCR

PRESS RELEASES

  • LILLE, 17TH JANUARY 2019

    OCR and ImaBiotech initiate a strategic partnership to provide in situ drug efficacy and target exposure services in Pets with naturally occuring tumors.

  • LILLE, 02ND NOVEMBER 2018

    OCR and Biofortis discuss the importance of the microbiome, especially in the field of oncology, in an interview with Dr Tierny and Dr Rybicka.

  • LILLE, 17TH SEPTEMBER 2018

    OCR together with ImmunXperts and Rarecells win k€520 funding in Eureka Eurostars program to initiate €1,3m “ICOM” platform for preclinical and clinical human cancer drug evaluation in pet dog’s model.

  • LILLE, 6TH SEPTEMBER 2016

    OCR the company revolutionising the selection of effective drug candidates for cancer, raises €1.25m from Newfund, NFA and the management team in order to accelerate its growth.

  • LILLE, 16TH JULY 2015

    OCR and Pierre Fabre’s Phase I Clinical Pharmacology Study published in prestigious Clinical Cancer Research journal.

  • LILLE, 02ND APRIL 2015

    OCR and Ecrins Therapeutics initiate €1.9m “Dog to Man” pioneering translational research programme to advance human and vet oncology treatment.

  • LILLE, 23RD MARCH 2015

    OCR and PRISM announce ground-breaking research collaboration to advance real-time diagnosis using mass spectrometry.

  • LILLE, 30TH JANUARY 2015

    OCR strengthens veterinary and R&D expertise to respond to the needs of the pharmaceutical industry.

Stay connected to OCR,
subscribe to our Newsletter !

Contact Us

WE WOULD BE DELIGHTED TO HEAR FROM YOU !

OCR FRANCE

Matthieu DUBRUQUE – CBO

mdubruque@oncovet-clinical-research.com

Tel. : +33 (0) 663 513 971

Parc Eurasanté – Lille Métropole

80 rue du Dr Yersin, 59120 Loos

OCR USA

BOSTON

bdcom@oncovet-clinical-research.com